Neurogene Inc. (NGNE:NASDAQ) closed at $23.55 on October 23, 2026, down 3.01% on the day. The stock trades 46.1% below its 52-week high of $43.66 and 47.8% above its 52-week low of $15.93. Over the past year, it lost 21.2%. Neurogene Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, NGNE closed higher on 122 days (48%). Its best day was February 27, 2026 (+19.36%) and its worst was November 13, 2025 (-14.77%). The stock moved 10% or more in a single session 12 times. It opened at least 5% above the previous day's high 2 times.
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
Find more stocks like NGNE with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.